Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0DFJAE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
KY-0301
|
|||||
| Synonyms |
KY-0301; RB-601?
Click to Show/Hide
|
|||||
| Organization |
Keyi Pharmaceutical (Originator);Radiance
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
|
|
||||||
| Antibody Name |
EGFR/c-Met bispecific nanobody
|
Antibody Info | Antigen Name | |||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Site-specific
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Colorectal cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|